Composition
Potassium citrate.
Presentation
Bottle, 100 Extended Release Tablets, 10 Millimeters.
Indications
Treatment of renal lithiasis.
Recurrence prophylaxis in the formation of kidney stones.
Posology
2 tablets per day up to 100 mEq.
Contraindications
Adrenal insufficiency, renal insufficiency, respiratory or metabolic alkalosis, intestinal obstruction, active gastric ulcer.
Adverse effects
Mild gastrointestinal disorders may occur, such as: dyspepsia, nausea, vomiting, diarrhea, which can be reduced by co-administration with food.
Interaction with other Medications
Drug interactions:
Concomitant administration of UROCIT® K and potassium-sparing diuretics should be avoided. MEDICINES THAT DELAY INTESTINAL TRANSIT TIME (such as anticholinergics) may increase the gastrointestinal irritation produced by potassium salts.
Laboratory tests:
Regular potassium determinations are recommended. Careful attention should be paid to the acid-base balance, levels of other serum electrolytes, the electrocardiogram, and the clinical status of the patient.
Warnings
Do not administer during pregnancy or when its existence is suspected, or during lactation. The active ingredient is released from the wax matrix to exert its effect. The matrix is an inert carrier and can be excreted unchanged in the feces.
